KOL | John Camm MD John CammSt George’s University, London, UK | Cardiology, St George's University of London, London, UK | Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, ... |
KOL Resume for John Camm MD John Camm
| Year | |
|---|---|
| 2022 | St George’s University, London, UK |
| 2021 | Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK Cardiology Clinical Academic Group, Molecular and Clinical Sciences Institute, St. George’s University of London, London, United Kingdom; St George's University, London, United Kingdom |
| 2020 | St George's University of London, Cardiology Clinical Academic Group Molecular & Clinical Sciences Research Institute,, London, United Kingdom |
| 2019 | Department of Clinical Cardiology, St. George’s University of London, London, UK Cardiology Clinical Academic Group Molecular & Clinical Sciences Research Institute, St. George’s University of London, London, United Kingdom St George’s University of London, London, England |
| 2018 | St George's University of London, UK (A.J.C.). Department of Genetics and Imaging, Faculty of Medicine, Imperial College London, London, UK. Imperial College London, London, United Kingdom |
John Camm MD John Camm: Influence Statistics
| Concept | World rank |
|---|---|
| period lvef | #1 |
| scd victims survivors | #1 |
| 160 patients permanent | #1 |
| baseline afb | #1 |
| heart rate levofloxacin | #1 |
| trials atrial | #1 |
| formal tqt study | #1 |
| artesia | #1 |
| ira patency brs | #1 |
| reduction atrial fibrillation | #1 |
| pacing physicians | #1 |
| 36 risk | #1 |
| patients automobile driving | #1 |
| progression health quality | #1 |
| met439thr substitution | #1 |
| rrmin | #1 |
| computerised measurements | #1 |
| atrial flutter probability | #1 |
| avfrp measurements | #1 |
| micropressor | #1 |
| prior lifethreatening events | #1 |
| vpb hrt | #1 |
| turbulence dynamics mortality | #1 |
| propafenone management | #1 |
| reduced atrioventricular | #1 |
| qt interval patients | #1 |
| broad complex tachycardia | #1 |
| xanap nvaf | #1 |
| recognition artefact | #1 |
| sx vgm | #1 |
| 24 recordings | #1 |
| treatment flecainide acetate | #1 |
| regression qt | #1 |
| nicm 95 | #1 |
| placebo recordings | #1 |
| lqts lqts vf | #1 |
| plateaudose | #1 |
| cardiac effects amiselimod | #1 |
| delay s1s2 interval | #1 |
| standard timedomain analysis | #1 |
| apb hrt | #1 |
| differences recordings | #1 |
| nhvt | #1 |
| sinus rhythm followup | #1 |
| combination lvef | #1 |
| skeberis george | #1 |
| cpvea | #1 |
| humans tdp | #1 |
| bridge 2 survey | #1 |
| relative risk wmi | #1 |
Open the FULL List in Excel | |
Prominent publications by John Camm MD John Camm
BACKGROUND: Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.
METHODS: We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial ...
| Known for New Oral Anticoagulants | Atrial Fibrillation | Randomised Trials | Systemic Embolic Events | Intracranial Haemorrhage |
OBJECTIVE: To attempt to determine the relative value of preclinical cardiac electrophysiology data (in vitro and in vivo) for predicting risk of torsade de pointes (TdP) in clinical use.
METHODS: Published data on hERG (or I(Kr)) activity, cardiac action potential duration (at 90% repolarisation; APD(90)), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs. These data were set against the free plasma concentrations attained during ...
| Known for Drugs Tdp | Clinical Qt | Herg Ikr | Humans Data | Safety Margin |
OBJECTIVES: We investigated whether heart rate variability, the signal-averaged electrocardiogram (ECG), ventricular arrhythmias and left ventricular ejection fraction predict the mechanism of cardiac death after myocardial infarction.
BACKGROUND: Postinfarction risk stratification studies have almost exclusively focused on predicting the risk of arrhythmic death. The factors that identify and distinguish persons at risk for arrhythmic and nonarrhythmic death are poorly known.
METHODS: ...
| Known for Arrhythmic Death | Ventricular Arrhythmias | Rate Variability | Ejection Fraction | Acute Myocardial |
The optimal atrioventricular delay at rest and during exercise was investigated in nine patients with heart block and implanted dual chamber pacemakers. All patients studied had normal left ventricular function and a normal sinus node rate response to exercise. Cardiac output was measured by continuous wave Doppler and was calculated as the product of stroke distance measured by Doppler at the left ventricular outflow, aortic root area measured by M mode echocardiography, and heart rate. ...
| Known for Atrioventricular Delay | Dual Chamber Pacemakers | Cardiac Output | Rest Exercise | Artificial Echocardiography |
To evaluate the potential prognostic value of the circadian variation of QT intervals in predicting sudden cardiac death (SCD) in patients after myocardial infarction (MI), 15 pairs of post-MI patients (15 died suddenly within 1 year after MI [SCD victims] and 15 remained event-free [MI survivors]) were studied (mean age 60 +/- 8 years; 24 men and 6 women). The pairs were matched for age, gender, infarct site, presence of Q wave, left ventricular ejection fraction, thrombolytic and ...
| Known for Qt Interval | Circadian Variation | Myocardial Infarction | Scd Victims | Normal Subjects |
Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF. Compared with warfarin, rivaroxaban significantly ...
| Known for Atrial Fibrillation | Latin America | Prevention Stroke | Patients Xantus | Routine Clinical Practice |
OBJECTIVES: This substudy tested a prospective hypothesis that European Myocardial Infarct Amiodarone Trial (EMIAT) patients with depressed heart rate variability (HRV) benefit from amiodarone treatment.
BACKGROUND: The EMIAT randomized 1,486 survivors of acute myocardial infarction (MI) aged < or =75 years with left ventricular ejection fraction (LVEF) < or =40% to amiodarone or placebo. Despite a reduction of arrhythmic mortality on amiodarone, all-cause mortality was not ...
| Known for Heart Rate | Patients Hrv | Prophylactic Treatment | Placebo Amiodarone | Allcause Mortality |
The current manuscript is the second update of the original Practical Guide, published in 2013 [Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651; Heidbuchel et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507]. ...
| Known for Patients Noacs | Atrial Fibrillation | Practical Guide | Heart Rhythm | Oral Anticoagulants |
| Known for Heart Association | European Society | Atrial Fibrillation | Task Force | Surgical Ablation |
The Changing Landscape for Stroke Prevention in AF Findings From the GLORIA-AF Registry Phase 2
[ PUBLICATION ]
BACKGROUND: GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available.
OBJECTIVES: This study sought to describe phase 2 baseline data and compare these with the ...
| Known for Atrial Fibrillation Patients | Antithrombotic Treatment | North America | Stroke Prevention | Changing Landscape |
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
[ PUBLICATION ]
BACKGROUND: Atrial fibrillation occurs frequently in patients with congestive heart failure and commonly results in clinical deterioration and hospitalization. Sinus rhythm may be maintained with antiarrhythmic drugs, but some of these drugs increase the risk of death.
METHODS: We studied 1518 patients with symptomatic congestive heart failure and severe left ventricular dysfunction at 34 Danish hospitals. We randomly assigned 762 patients to receive dofetilide, a novel class III ...
| Known for Congestive Heart Failure | Dofetilide Atrial Fibrillation | Sinus Rhythm | Hazard Ratio | Risk Death |
Decreased heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease.
[ PUBLICATION ]
BACKGROUND: Although heart rate variability has already been studied in survivors of sudden cardiac death secondary to coronary artery disease, an assessment of heart rate variability in survivors of sudden cardiac death not associated with coronary artery disease has not been made.
METHODS: 10 patients with aborted sudden cardiac death not associated with coronary artery disease (seven patients with primary ventricular fibrillation and three with unclassified mild cardiomyopathy) ...
| Known for Heart Rate | Sudden Cardiac Death | Coronary Artery Disease | Cardiac Electrocardiography | 24 Hours |
Resting heart rate is associated with cardiovascular and all-cause mortality, and the mortality benefit of some cardiovascular drugs seems to be related in part to their heart rate-lowering effects. Since it is difficult to separate the benefit of heart rate lowering from other actions with currently available drugs, a ‘pure’ heart rate-lowering drug would be of great interest in establishing the benefit of heart rate reduction per se.Heart rate is determined by spontaneous electrical ...
| Known for Heart Rate | Current Inhibition | Patients Stable Angina | Ivabradine Myocardial | Diastolic Depolarisation |
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks.
DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent ...
| Known for Atrial Fibrillation | Mortality Stroke | Bleeding Risk | Patients Anticoagulation | Cha2ds2 Vasc |
BACKGROUND: It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied.
METHODS: We conducted a multicenter, randomized trial ...
| Known for Rhythm Control | Atrial Fibrillation | Heart Failure | Death Patients | Ventricular Rate |
Key People For Atrial Fibrillation
John Camm MD John Camm:Expert Impact
Concepts for whichJohn Camm MD John Cammhas direct influence:Atrial fibrillation, Myocardial infarction, Heart rate, Ventricular tachycardia, Qt interval, Heart rate variability, Sinus rhythm, Heart failure.
John Camm MD John Camm:KOL impact
Concepts related to the work of other authors for whichfor which John Camm MD John Camm has influence:Atrial fibrillation, Heart failure, Catheter ablation, Myocardial infarction, Blood pressure, Sudden cardiac death, Oral anticoagulants.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |